Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Pharmacokinetics of non-intravenous formulations of fentanyl.

Lötsch J, Walter C, Parnham MJ, Oertel BG, Geisslinger G.

Clin Pharmacokinet. 2013 Jan;52(1):23-36. doi: 10.1007/s40262-012-0016-7. Review.

PMID:
23100195
2.

New formulations of fentanyl for acute pain management.

Paech MJ, Bloor M, Schug SA.

Drugs Today (Barc). 2012 Feb;48(2):119-32. doi: 10.1358/dot.2012.48.2.1745275. Review.

PMID:
22384452
3.
4.

Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl.

Grond S, Radbruch L, Lehmann KA.

Clin Pharmacokinet. 2000 Jan;38(1):59-89. Review.

PMID:
10668859
6.

Pain treatment with opioids : achieving the minimal effective and the minimal interacting dose.

Geppetti P, Benemei S.

Clin Drug Investig. 2009;29 Suppl 1:3-16. doi: 10.2165/0044011-200929001-00002. Review.

PMID:
19445550
7.

Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.

Scholz J, Steinfath M, Schulz M.

Clin Pharmacokinet. 1996 Oct;31(4):275-92. Review.

PMID:
8896944
8.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
9.
10.

Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.

Elsner F, Zeppetella G, Porta-Sales J, Tagarro I.

Clin Drug Investig. 2011;31(9):605-18. doi: 10.2165/11592910-000000000-00000. Review.

PMID:
21819159
11.

The use of long-acting opioids in chronic pain management.

Vallerand AH.

Nurs Clin North Am. 2003 Sep;38(3):435-45. Review.

PMID:
14567201
12.

A review of the pharmacokinetic profile of transmucosal fentanyl formulations.

Moore N, Darwish M, Amores X, Schneid H.

Curr Med Res Opin. 2012 Nov;28(11):1781-90. doi: 10.1185/03007995.2012.735227. Epub 2012 Oct 18. Review.

PMID:
23020252
13.

Iontophoretic drug delivery system: focus on fentanyl.

Herndon CM.

Pharmacotherapy. 2007 May;27(5):745-54. Review.

PMID:
17461710
14.

Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.

Dietrich E, Gums JG.

Ann Pharmacother. 2012 Oct;46(10):1382-91. doi: 10.1345/aph.1R069. Epub 2012 Sep 25. Review.

PMID:
23012382
15.

Fentanyl buccal tablet.

Messina J, Darwish M, Fine PG.

Drugs Today (Barc). 2008 Jan;44(1):41-54. doi: 10.1358/dot.2008.44.1.1178469. Review.

PMID:
18301803
16.

Treatment of cancer pain with transdermal fentanyl.

Gourlay GK.

Lancet Oncol. 2001 Mar;2(3):165-72. Review.

PMID:
11902567
17.

Pediatric palliative care: use of opioids for the management of pain.

Zernikow B, Michel E, Craig F, Anderson BJ.

Paediatr Drugs. 2009;11(2):129-51. doi: 10.2165/00148581-200911020-00004. Review.

PMID:
19301934
18.

Fentanyl for breakthrough pain: a systematic review.

Davis MP.

Expert Rev Neurother. 2011 Aug;11(8):1197-216. doi: 10.1586/ern.11.63. Review.

PMID:
21797660
19.

Transdermal therapeutic fentanyl-system (TTS-F).

Mystakidou K, Katsouda E, Tsilika E, Parpa E, Vlahos L.

In Vivo. 2004 Sep-Oct;18(5):633-42. Review.

20.

Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics.

Mystakidou K, Katsouda E, Parpa E, Vlahos L, Tsiatas ML.

Drug Deliv. 2006 Jul-Aug;13(4):269-76. Review.

PMID:
16766468
Items per page

Supplemental Content

Write to the Help Desk